Genesis of hepatic fibrosis and its biochemical markers

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 4, 2008, Pages 260-269

  Das, S K ^a   Vasudevan, D M ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Collagen; Cytokines; Extracellular matrix; Fibrosis; Hepatic stellate cell; Hyaluronic acid; Interleukins; Matrix metalloproteinases; Transforming growth factor beta

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN FIBER; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; ECHOGRAPHY; EXTRACELLULAR MATRIX; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STELLATE CELL;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; EXTRACELLULAR MATRIX; HEPATOCYTES; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS;

EID: 46949105856     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701668516     Document Type: Review

References (92)

1. Friedman SL, Bansal MB. Reversal of hepatic fibrosis: fact or fantasy. Hepatology 2006;43:S82-8.
2. Kisseleva T, Brenner DA. Hepatic stellate cells and the reversal of fibrosis. J Gastroenterol Hepatol 2006;21 Suppl 3:S84-7.
3. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247-50.
4. Alcolado R, Arthur MJ, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci (Lond) 1997;92:103-12.
5. Sarem M, Znaidak R, Macias M, Rey R. Hepatic stellate cells: their role in normal and pathological conditions. Gastroenterol Hepatol 2006;29:93-101.
6. Reeves HL, Friedman SL. Activation of hepatic stellate cells - a key issue in liver fibrosis. Front Biosci 2002;7:d808-26.
7. Marra F. Chemokines in liver inflammation and fibrosis. Front Biosci 2002;7:d1899-914.
8. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004;126:529-40.
9. Efsen E, Grappone C, DeFranco RM, Milani S, Romanelli RG, Bonacchi A, et al. Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans. J Hepatol 2002;37:39-47.
10. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003;37:1043-55.
11. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003;299:890-3.
12. Olaso E, Salado C, Egilegor E, Gutierrez V, Santisteban A, Sancho-Bru P, et al. Proangiogenic role of tumor-activated hepatic stellate cells in experimental melanoma metastasis. Hepatology 2003;37:674-85.
13. Ankoma-Sey V, Wang Y, Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology 2000;31:141-8.
14. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987;6:1899-904.
15. Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003;26:1-9.
16. Miyahara T, Schrum L, Rippe R, Xiong S, Yee HF Jr, Motomura K, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-22.
17. Kim KH, Kim HC, Hwang MY, Oh HK, Lee TS, Chang YC, et al. The antifibrotic effect of TGF-beta1 siRNAs in murine model of liver cirrhosis. Biochem Biophys Res Commun 2006;343:1072-8.
18. Zhan SS, Jiang JX, Wu J, Halsted C, Friedman SL, Zern MA, et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006;43:435-43.
19. Inagaki Y, Kushida M, Higashi K, Itoh J, Higashiyama R, Hong YY, et al. Cell type-specific intervention of transforming growth factor beta/Smad signaling suppresses collagen gene expression and hepatic fibrosis in mice. Gastroenterology 2005;129:259-68.
20. Uemura M, Swenson ES, Gaca MD, Giordano FJ, Reiss M, Wells RG. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell 2005;16:4214-24.
21. Tsukada S, Westwick JK, Ikejima K, Sato N, Rippe RA. SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem 2005;280:10055-64.
22. Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001;21:351-72.
23. Lauria V, Tariciotti G, Festuccia F, Attili AF. The physiopathological mechanism of hepatic fibrosis. Minerva Gastroenterol Dietol 1998;44:149-58.
24. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001;21:427-36.
25. Iredale JP, Benyon RC, Arthur MJ, Ferris WF, Alcolado R, Winwood PJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis. Hepatology 1996;24:176-84.
26. Roeb E, Purucker E, Breuer B, Nguyen H, Heinrich PC, Rose-John S, et al. TIMP expression in toxic and cholestatic liver injury in rat. J Hepatol 1997;27:535-44.
27. Schaefer B, Rivas-Estilla AM, Meraz-Cruz N, Reyes-Romero MA, Hernandez-Nazara ZH, Dominguez-Rosales JA, et al. Reciprocal modulation of matrix metalloproteinase-13 and type I collagen genes in rat hepatic stellate cells. Am J Pathol 2003;162:1771-80.
28. Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y. Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272:2446-51.
29. Preaux AM, Mallat A, Nhieu JT, D'Ortho MP, Hembry RM, Mavier P. Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions. Hepatology 1999;30:944-50.
30. Xu GF, Li PT, Wang XY, Jia X, Tian DL, Jiang LD, et al. Dynamic changes in the expression of matrix metalloproteinases and their inhibitors, TIMPs, during hepatic fibrosis induced by alcohol in rats. World J Gastroenterol 2004;10:3621-7.
31. Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H. Serum matrix metalloproteinase-3 (stromelysin-1) concentration in patients with chronic liver disease. J Hepatol 1999;31:474-81.
32. Zhu YK, Wang BE, Shen FJ, Wang AM, Jia JD, Ma H. Dynamic evolution of MMP-13, TIMP-1, type I and III collagen and their interaction in experimental liver fibrosis. Zhonghua Gan Zang Bing Za Zhi 2004;12:612-15.
33. Zhou X, Hovell CJ, Pawley S, Hutchings MI, Arthur MJ, Iredale JP, et al. Expression of matrix metalloproteinase-2 and -14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis. Liver Int 2004;24:492-501.
34. Bataller R, Sancho-Bru P, Gines P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 2005;7:1346-55.
35. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004;84:766-77.
36. Gabele E, Reif S, Tsukada S, Bataller R, Yata Y, Morris T, et al. The role of p70S6K in hepatic stellate cell collagen gene expression and cell proliferation. J Biol Chem 2005;280:13374-82.
37. Geremias AT, Carvalho MA, Borojevic R, Monteiro AN. TGF beta1 and PDGF AA override collagen type I inhibition of proliferation in human liver connective tissue cells. BMC Gastroenterol 2004;4:30.
38. Cai WM, Zhang BB, Weng HL, Hu ZR, Lv J, Zheng M, et al. [The diagnostic value of eight serum indices for liver fibrosis. ] Zhonghua Gan Zang Bing Za Zhi 2004;12:219-22.
39. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, Haran AC, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005;102:3389-94.
40. Arthur MJ, Iredale JP. Hepatic lipocytes, TIMP-1 and liver fibrosis. J R Coll Phys Lond 1994;28:200-8.
41. Neubauer K, Saile B, Ramadori G. Liver fibrosis and altered matrix synthesis. Can J Gastroenterol 2001;15:187-93.
42. Desmet VJ, Roskams T. Cirrhosis reversal: a duel between dogma and myth. J Hepatol 2004;40:860-7.
43. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alpha-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-13.
44. Issa R, Zhou X, Constandinou CM, Fallowfield J, Millward-Sadler H, Gaca MD, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004;126:1795-808.
45. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-26.
46. Das SK, Dhanya L, Vasudevan DM. Biomarkers of alcoholism: an updated review. Scand J Clin Lab Invest. In press.
47. Das SK, Balakrishnan V, Vasudevan DM. Utility of serum hydroxyproline, type IV collagen and AST to platelet ratio index (APRI) in the prediction of liver damage. Clin Chem 2007;S6:A77 [abstract].
48. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance as probability index. Hepatology 2004;39:1239-47.
49. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-81.
50. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haemotol 2001;113:590-5.
51. Kamimoto Y, Horiuchi S, Tanase S, Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isoenzymes; evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985;5:367-75.
52. Nandi A, Estess P, Siegelman MH. Hyaluronan anchoring and regulation on the surface of vascular endothelial cells is mediated through the functionally active form of CD44. J Biol Chem 2000;275:14939-48.
53. Vrochides D, Papanikalaou V, Pertoft H, Antoniads AA, Heldin P. Biosynthesis and degradation of hyaluranon by nonparenchymal liver cells during liver regeneration. Hepatology 1996;23:1650-5.
54. Fraser JR, Gibson PR. Mechanisms by which food intake elevated circulating levels of hyaluronan in humans. J Intern Med 2005;258:460-6.
55. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005;43:78-84.
56. Kivirikko KI. Collagens and their abnormalities in a wide spectrum of diseases. Ann Med 1993;25:113-26.
57. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type 3 procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42:558-63.
58. Gabrielli GB, Corrocher R. Hepatic fibrosis and its serum markers: a review. Dig Dis Sci 1991;9:303-16.
59. Maruyama K, Okazaki I, Takagi T, Ishii H. Formation and degradation of basement membrane collagen. Alcohol Alcohol Suppl 1991;1:369-74.
60. Santos VN, Leite-Mor MM, Kondo M, Martins JR, Nader H, Lanzoni VP, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005;38:747-53.
61. Lee HS, Shun CT, Chiou LL, Chen CH, Huang GT, Sheu JC. Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: emphasis on sampling variability. J Gastroenterol Hepatol 2005;20:1109-14.
62. Wyszomirska RM, Nishimura NF, Almeida JR, Yamanaka A, Soares EC. High serum laminin and type IV collagen levels in schistosomiasis mansoni. Arq Gastroenterol 2005;42:221-5.
63. Tsukamoto T, Yamamoto T, Ikebe T, Takemura S, Shuto T, Kubo S, et al. Serum markers of liver fibrosis and histologic severity of fibrosis in resected liver. Hepatogastroenterology 2004;51:777-80.
64. Hirayama C, Suzuki H, Takada A, Fujisawa K, Tanikawa K, Igarashi S. Serum type IV collagen in various liver diseases in comparison with serum 7S collagen, laminin, and type III procollagen peptide. J Gastroenterol 1996;31:242-8.
65. Ponmarenko Y, Anna Leo M, Kroll W, Lieber CS. Effects of alcohol consumption on 8 circulating markers of liver fibrosis. Alcohol Alcohol 2002;37:252-5.
66. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002;277:11069-76.
67. Tsukada S, Parsons CJ, Rippe RA. Mechanism of liver fibrosis. Clin Chem Acta 2006;364:33-60.
68. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000;32:911-20.
69. Bigg HF, Wait R, Rowan AD, Cawston TE. The mammalian chitinase - like lectin, YKL-40, binds specifically to type 1 collagen and modulates the rate of type 1 collagen fibril formation. J Biol Chem 2006;281:210282-95.
70. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006;15:194-202.
71. Chen Y, Wang BE, Jia JD, Qian LX, Wang TL, Chen MH, et al. Noninvasive evaluation of liver fibrosis in chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 2003;11:354-7.
72. Liu J, Wang JY, Lu Y. Serum fibrosis markers in diagnosing liver fibrosis. Zhonghua Nei Ke Za Zhi 2006;45:475-7.
73. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-42.
74. Mukherjee S, Sorrell MF. Noninvasive tests for liver fibrosis. Semin Liver Dis 2006;26:337-47.
75. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-13.
76. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.
77. Kawamoto M, Mizuguchi T, Katsuramaki T, Nagayama M, Oshima H, Kawasaki H, et al. Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers. World J Gastroenterol 2006;12:4325-30.
78. McClain C, Barve S, Joshi-Barve S, Song Z, Deaciuc I, Chen T, et al. Dysregulated cytokine metabolism, altered hepatic methionine metabolism and proteasome dysfunction in alcoholic liver disease. Alcohol Clin Exp Res 2005;29:180S-8S.
79. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepatol 2001;8:430-7.
80. Akpolat N, Yahsi S, Godekmerdan A, Demirbag K, Yalniz M. Relationship between serum cytokine levels and histopathological changes of liver in patients with hepatitis B. World J Gasteroenterol 2005;11:3260-3.
81. Musso G, Gambino R, Biroli G, Carello M, Faga E, Pacini G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005;100:2438-46.
82. Day CP. Genetic studies to identify hepatic fibrosis genes and SNP's in human populations. Methods Mol Med 2005;117:315-31.
83. Patel K, Norris S, Lebeck L, Feng A, Clare M, Pianko S, et al. HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. Hepatology 2006;43:241-9.
84. Bataller R, North KE, Brenner Da. Genetic polymorphism and the progression of liver fibrosis: a critical appraisal. Hepatology 2003;37:493-503.
85. Kamal SM, Turner B, He Q, Rasenack J, Bianchi L, Al Tawil A, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006;43:771-9.
86. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10:429-34.
87. Seeger C, Mason WS. Hepatitis B virus biology. Microbial Mol Biol Rev 2000;64:51-68.
88. Weiss J, Wu H, Farrenkopf B, Schultz T, Song G, Shah S, et al. Real-time TaqMan PCR detection and quantitation of HBV genotypes A-G with the use of an internal quantitation standard. J Clin Virol 2004;30:86-93.
89. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84.
90. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HbeAg-positive chronic hepatitis B: a radomised trial. Lancet 2005;365:123-9.
91. Schildgen O, Sirma H, Funk A, Olotu C, Wend UC, Hartmann H, et al. Variant of hepatitis B virus with primary resistence to adefovir. N Engl J Med 2006;354:1807-12.
92. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-88.